Researchliraglutidediabetic-keratopathyglp-1-receptorpreclinical

Liraglutide speeds diabetic corneal epithelial repair in mice via Nrf2, PI3K/Akt

Researchers localised GLP-1 receptor to deep basal corneal epithelial cells and found PI3K inhibition abolished the drug's effect on proliferation and migration.

By Priya Raman · Science Reporter

Aug 31 20:00 ETSource: Investigative ophthalmology & visual science

The wire

01In streptozotocin-diabetic mice and 30 mM high-glucose cell models, liraglutide improved epithelial viability, proliferation and migration, cut apoptosis and restored redox balance through Nrf2/HO-1/NQO-1 signalling.
02Suggests a possible ocular surface application for an approved GLP-1 agonist in diabetic keratopathy, a complication with few targeted options.
03Findings are limited to mouse and cell models with no human dosing, route or safety data for topical or systemic use in corneal disease.

From the source

Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing
Investigative ophthalmology & visual science · 2026 Sep 1 · Liu X, Lin H, Shao Y et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42808829/